{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:32Z","timestamp":1793183192788,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007493","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007493","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007818","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019266","name":"GlaxoSmithKline Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi Aventis GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.yebeh.2024.110024","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T23:02:55Z","timestamp":1725145375000},"page":"110024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3278-3524","authenticated-orcid":false,"given":"Susanna","family":"Stjerna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yfke","family":"Huber-Mollema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-5352","authenticated-orcid":false,"given":"Torbj\u00f6rn","family":"Tomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-223X","authenticated-orcid":false,"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-9986","authenticated-orcid":false,"given":"Dina","family":"Battino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-9795","authenticated-orcid":false,"given":"John","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sabers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eija","family":"Gaily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.110024_b0055","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/pds.5035","article-title":"Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006\u20132016: A study in the five Nordic countries, United States, and Australia","volume":"29","author":"Cohen","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2024.110024_b0020","article-title":"Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy","volume":"Mar 18:e240258","author":"Battino","year":"2024","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110024_b0060","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.26561","article-title":"Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations","volume":"93","author":"Cohen","year":"2023","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110024_b0145","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1017\/S0012162205001076","article-title":"Characteristics of fetal anticonvulsant syndrome associated autism disorder","volume":"47","author":"Rasalam","year":"2005","journal-title":"Dev Med Child Neurol"},{"issue":"16","key":"10.1016\/j.yebeh.2024.110024_b0045","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2024.110024_b0030","doi-asserted-by":"crossref","first-page":"e034829","DOI":"10.1136\/bmjopen-2019-034829","article-title":"Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study","volume":"10","author":"Bloti\u00e8re","year":"2020","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110024_b0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.yebeh.2024.110024_b0095","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2309359","article-title":"Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure","volume":"390","author":"Hern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2024.110024_b0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2024.110024_b0040","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1212\/WNL.0000000000003157","article-title":"Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate","volume":"87","author":"Bromley","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110024_b0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.0000000000001182","article-title":"IQ at 6 years after in utero exposure to antiepileptic drugs","volume":"84","author":"Baker","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110024_b0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1212\/WNL.62.1.28","article-title":"Normal intelligence in children with prenatal exposure to carbamazepine","volume":"62","author":"Gaily","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110024_b0115","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1212\/WNL.0000000000006073","article-title":"Verbal abilities in children of mothers with epilepsy","volume":"91","author":"Husebye","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110024_b0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1017\/S1355617707070804","article-title":"Neuropsychological outcomes in children of mothers with epilepsy","volume":"13","author":"Kantola-Sorsa","year":"2007","journal-title":"J Internat Neuropsychol Soc"},{"key":"10.1016\/j.yebeh.2024.110024_b0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.yebeh.2018.12.031","article-title":"Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study","volume":"92","author":"Cohen","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110024_b0015","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1037\/neu0000465","article-title":"Memory Dysfunction in School-Aged Children Exposed Prenatally to Antiepileptic Drugs","volume":"32","author":"Barton","year":"2018","journal-title":"Neuropsychology"},{"key":"10.1016\/j.yebeh.2024.110024_b0035","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/1570159X19666210716111814","article-title":"Neurodevelopment Following Exposure to Antiseizure Medications in Utero: A Review","volume":"19","author":"Bromley","year":"2021","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110024_b0100","doi-asserted-by":"crossref","first-page":"e209175","DOI":"10.1212\/WNL.0000000000209175","article-title":"Neurodevelopmental and Functional Outcomes Following In Utero Exposure to Antiseizure Medication: A Systematic Review","volume":"102","author":"Honybun","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110024_b0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jamaneurol.2023.0674","article-title":"Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders","volume":"80","author":"Dreier","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2024.110024_b0150","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1212\/WNL.0000000000201529","article-title":"Prenatal Carbamazepine Exposure and Academic Performance in Adolescents","volume":"100","author":"Ren","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110024_b0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamaneurol.2023.4315","article-title":"Behavioral Outcomes and Neurodevelopmental Disorders Among Children of Women With Epilepsy","volume":"81","author":"Cohen","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2024.110024_b0125","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/epi.16953","article-title":"Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review","volume":"62","author":"Knight","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110024_b0085","unstructured":"EURAP Extension Protocol # 2. Neurocognitive Extension Protocol (NCEP) for children exposed to antiepileptic drugs in utero. https:\/\/eurapinternational.org\/wp-content\/uploads\/2018\/03\/NCEP_protocol_revised2011.pdf."},{"key":"10.1016\/j.yebeh.2024.110024_b0110","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00415-020-09764-w","article-title":"Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure","volume":"267","author":"Huber-Mollema","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2024.110024_b0140","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/brain\/aws356","article-title":"Phonological deficits in specific language impairment and developmental dyslexia: towards a multidimensional model","volume":"136","author":"Ramus","year":"2013","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110024_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0265659016654206","article-title":"Working memory and language learning: A review","volume":"33","author":"Archibald","year":"2017","journal-title":"Child Lang Teach Ther"},{"key":"10.1016\/j.yebeh.2024.110024_b0155","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fnhum.2018.00517","article-title":"Behind the Scenes of Developmental Language Disorder: Time to Call Neuropsychology Back on Stage","volume":"12","author":"Tomas","year":"2018","journal-title":"Front Hum Neurosci"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110024_b0105","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/epi.15968","article-title":"Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy","volume":"60","author":"Huber-Mollema","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110024_b0160","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.neubiorev.2011.12.008","article-title":"Face identity recognition in autism spectrum disorders: A review of behavioral studies","volume":"36","author":"Weigelt","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.yebeh.2024.110024_b0135","doi-asserted-by":"crossref","first-page":"e1438","DOI":"10.1002\/wcs.1438","article-title":"\u201cForm is easy, meaning is hard\u201d revisited: (re) characterizing the strengths and weaknesses of language in children with autism spectrum disorder","volume":"8","author":"Naigles","year":"2017","journal-title":"WIREs Cogn Sci"},{"key":"10.1016\/j.yebeh.2024.110024_b0070","doi-asserted-by":"crossref","unstructured":"Degremont A, Kerbrat S, Balusson F, onville-Bera AP, Ringa V, Travers D, et al. Prescribing Trends for Valproate Among Pregnant Women. A Cross-sectional Study in 2013 and 2016 Using the French Health Insurance Database. Neurology 2022;98:e2163-e2173. doi:10.1212\/WNL.0000000000200260.","DOI":"10.1212\/WNL.0000000000200260"},{"key":"10.1016\/j.yebeh.2024.110024_b0075","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/epi.17526","article-title":"Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian study","volume":"64","author":"Di Vito","year":"2023","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024004062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024004062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:16:15Z","timestamp":1726373775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024004062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"alternative-id":["S1525505024004062"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110024","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110024"}}